These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 16123474

  • 1. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
    Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH.
    Diabetes Care; 2005 Sep; 28(9):2106-12. PubMed ID: 16123474
    [Abstract] [Full Text] [Related]

  • 2. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
    Rossing K, Jacobsen P, Pietraszek L, Parving HH.
    Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
    Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH.
    Kidney Int; 2006 Aug; 70(3):536-42. PubMed ID: 16775595
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.
    Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
    [Abstract] [Full Text] [Related]

  • 8. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

  • 9. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
    Schjoedt KJ, Astrup AS, Persson F, Frandsen E, Boomsma F, Rossing K, Tarnow L, Rossing P, Parving HH.
    Diabetologia; 2009 Jan; 52(1):46-9. PubMed ID: 18974967
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [Abstract] [Full Text] [Related]

  • 17. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
    Lacourcière Y, Bélanger A, Godin C, Hallé JP, Ross S, Wright N, Marion J.
    Kidney Int; 2000 Aug; 58(2):762-9. PubMed ID: 10916100
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 19. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
    Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD.
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
    [Abstract] [Full Text] [Related]

  • 20. Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
    Schjoedt KJ, Christensen PK, Jorsal A, Boomsma F, Rossing P, Parving HH.
    Nephrol Dial Transplant; 2009 Nov; 24(11):3343-9. PubMed ID: 19561152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.